Drugs / Dulanermin
Dulanermin
also known as
AMG 951 · Apo2L · APO2L/TRAIL · B lymphocyte stimulator (human) · Dulanermin for injection · Dulanermina · Dulanermine · rhApo2L/TRAIL · +1 more
Protein / enzyme biologic targets TNFRSF10A, TNFRSF10B via activation
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00873756 | May 2009 → Mar 2014 | colorectal cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00671372 | Jul 2006 → Mar 2012 | colorectal cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00400764 | Jun 2006 → May 2010 | indolent B-cell non-Hodgkin lymphoma | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00508625 | Jun 2006 → Mar 2009 | non-small cell lung carcinoma | Amgen | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03083743 | Oct 2016 → Oct 2017 | non-small cell lung carcinoma | Shanghai Gebaide Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dulanermin | “Dulanermin for injection” NCT03083743 ↗ |
| Known as | AMG 951 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00508625 ↗ |
| Known as | Apo2L | “Dulanermin-a non-polyhistidine-tagged soluble recombinant human apoptosis ligand 2 (Apo2L) or tumour-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-has pro-apoptotic...” PMID 26687959 ↗ Mar 2015 |
| Known as | APO2L/TRAIL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107846 ↗ |
| Known as | B lymphocyte stimulator (human) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107846 ↗ |
| Known as | Dulanermin for injection | “Dulanermin for injection” NCT03083743 ↗ |
| Known as | Dulanermina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107846 ↗ |
| Known as | Dulanermine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107846 ↗ |
| Known as | rhApo2L/TRAIL | “AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4...” NCT00508625 ↗ |
| Known as | TRAIL | “Dulanermin-a non-polyhistidine-tagged soluble recombinant human apoptosis ligand 2 (Apo2L) or tumour-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-has pro-apoptotic...” PMID 26687959 ↗ Mar 2015 |
| Action | Activate | “Tumor necrosis factor receptor superfamily member 10B agonist” CHEMBL2107846 ↗1“TRAIL receptor-1 agonist” CHEMBL2107846 ↗ |
| Modality | Protein / enzyme biologic | “Dulanermin-a non-polyhistidine-tagged soluble recombinant human apoptosis ligand 2 (Apo2L) or tumour-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-has pro-apoptotic...” PMID 26687959 ↗ Mar 2015 |
| Route | Intravenous | “Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.” NCT00400764 ↗ |
| Target | TNFRSF10A | “TRAIL receptor-1 agonist” CHEMBL2107846 ↗ |
| Target | TNFRSF10B | “Tumor necrosis factor receptor superfamily member 10B agonist” CHEMBL2107846 ↗ |